首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1459609

全球生物製品市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Biologics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年03月01日 | 出版商:

Value Market Research | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球生物製剂市场需求预计将从 2023 年的 5,530.9 亿美元达到近 10,288.7 亿美元的市场规模，2024-2032 年研究期间CAGR为 7.14%。

生物製品是源自活生物体或其成分的药物，包括蛋白质、核酸、碳水化合物或细胞。与化学合成的小分子传统药物不同，生物製剂是利用重组 DNA 技术、细胞培养或微生物发酵等生物技术製程生产的。生物製剂包括各种治疗剂，包括单株抗体、细胞激素、荷尔蒙、酵素、疫苗和基因疗法，用于治疗多种疾病，如癌症、自体免疫疾病、传染病和遗传性疾病。

市场动态

癌症、自体免疫疾病和代谢疾病等慢性疾病的盛行率不断上升，推动了市场对提供针对性和个人化治疗选择的生物疗法的需求。生物製剂是从细胞、组织、蛋白质等生物体中提取的大分子药物，与传统小分子药物相比，具有特异性更高、副作用减少、疗效提高等优点。此外，生物技术、基因组学和免疫学的进步推动了生物药物发现、开发和製造流程的创新，使製造商能够开发新的生物疗法来满足未满足的医疗需求。此外，监管机构、医疗保健提供者和患者对生物製剂的接受度不断提高，加上报销范围和市场准入的不断扩大，正在加速生物製剂治疗在肿瘤学、风湿病学、皮肤病学和胃肠病学等各治疗领域的市场采用。此外，在医疗保健支出增加、中产阶级人口扩大和医疗保健服务可及性改善的推动下，新兴经济体不断扩大的市场机会正在刺激对生物製剂的需求，作为国家医疗保健政策和全民健康覆盖倡议的一部分。此外，製药公司、生技新创公司和学术机构不断增加研发投资，以发现和开发新型生物疗法，包括单株抗体、重组蛋白和细胞疗法，正在推动市场创新和成长。此外，在基因组定序、生物标记识别和患者分层的进步推动下，个人化医疗和精准医疗保健的不断增长趋势正在为针对个别患者概况和疾病特征量身定制的标靶生物疗法创造市场机会。然而，高生产成本、监管障碍以及生物相似药产品的竞争可能会阻碍市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球生物製品市场的各个细分市场进行了包容性评估。生物製品产业的成长和趋势为本研究提供了整体方法。

市场区隔

生物製剂市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按产品分类

单株抗体
重组蛋白
疫苗
细胞与基因治疗
其他的

按申请

肿瘤学
自体免疫和免疫疾病
血液系统疾病
传染性疾病
其他（心血管疾病等）

按製造

外包
内部

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲生物製品市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。生物製剂市场的主要参与者包括艾伯维、安进、阿斯特捷利康、百时美施贵宝公司、礼来公司、吉利德科学公司、葛兰素史克、强生服务公司、默克公司、诺华公司、辉瑞公司Inc.，F.霍夫曼-拉罗氏股份公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：生物製品公司的竞争格局

生物製品市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

公司股份分析
市场集中度
AbbVie

公司简介
公司收入
产品
最近的发展

Amgen

公司简介
公司收入
产品
最近的发展

AstraZeneca

公司简介
公司收入
产品
最近的发展

Bristol-Myers Squibb Company

公司简介
公司收入
产品
最近的发展

Eli Lilly

公司简介
公司收入
产品
最近的发展

Gilead Sciences Inc.

公司简介
公司收入
产品
最近的发展

GlaxoSmithKline

公司简介
公司收入
产品
最近的发展

Johnson & Johnson Services Inc.

公司简介
公司收入
产品
最近的发展

Merck & Co. Inc.

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

F. Hoffmann-La Roche AG

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112114075

The global demand for Biologics Market is presumed to reach the market size of nearly USD 1028.87 Billion by 2032 from USD 553.09 Billion in 2023 with a CAGR of 7.14% under the study period 2024 - 2032.

Biologics are pharmaceutical drugs derived from living organisms or their components, including proteins, nucleic acids, carbohydrates, or cells. Unlike small-molecule traditional medicines chemically synthesized, biologics are produced using biotechnological processes such as recombinant DNA technology, cell culture, or microbial fermentation. Biologics encompass various therapeutic agents, including monoclonal antibodies, cytokines, hormones, enzymes, vaccines, and gene therapies, used to address multiple medical conditions such as cancer, autoimmune diseases, infectious diseases, and genetic disorders.

MARKET DYNAMICS

The escalating prevalence of chronic diseases like cancer, autoimmune disorders, and metabolic diseases is driving market demand for biological therapies that offer targeted and personalized treatment options. Biologics are large molecule drugs derived from living organisms such as cells, tissues, and proteins, offering advantages such as higher specificity, reduced side effects, and improved efficacy compared to traditional small molecule drugs. Additionally, biotechnology, genomics, and immunology advancements propel innovation in biologic drug discovery, development, and manufacturing processes, enabling manufacturers to develop novel biologic therapies for unmet medical needs. Moreover, the growing acceptance of biologics by regulatory agencies, healthcare providers, and patients, coupled with increasing reimbursement coverage and market access, is accelerating the market adoption of biologic treatments in various therapeutic areas such as oncology, rheumatology, dermatology, and gastroenterology. Furthermore, the expanding market opportunities in emerging economies, driven by rising healthcare expenditures, expanding middle-class populations, and improving access to healthcare services, are stimulating demand for biologics as part of national healthcare policies and universal health coverage initiatives. Additionally, the increasing investments in research and development by pharmaceutical companies, biotechnology startups, and academic institutions to discover and develop novel biologic therapies, including monoclonal antibodies, recombinant proteins, and cell-based therapies, are driving market innovation and growth. Moreover, the growing trend of personalized medicine and precision healthcare, fueled by advances in genomic sequencing, biomarker identification, and patient stratification, is creating market opportunities for targeted biologic therapies tailored to individual patient profiles and disease characteristics. However, high production costs, regulatory hurdles, and competition from biosimilar products may hinder market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of biologics. The growth and trends of biologics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the biologics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Monoclonal Antibodies
Recombinant Proteins
Vaccines
Cell & Gene Therapy
Others

By Application

Oncology
Autoimmune & Immunological Disorders
Hematological Disorders
Infectious Diseases
Others (Cardiovascular Disorders, Etc.)

By Manufacturing

Outsourced
In-House

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Biologics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Biologics market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . BIOLOGICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Manufacturing
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL BIOLOGICS MARKET ANALYSIS BY PRODUCT

5.1 Overview by Product
5.2 Historical and Forecast Data
5.3 Analysis by Product
5.4 Monoclonal Antibodies Historic and Forecast Sales by Regions
5.5 Recombinant Proteins Historic and Forecast Sales by Regions
5.6 Vaccines Historic and Forecast Sales by Regions
5.7 Cell & Gene Therapy Historic and Forecast Sales by Regions
5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL BIOLOGICS MARKET ANALYSIS BY APPLICATION

6.1 Overview by Application
6.2 Historical and Forecast Data
6.3 Analysis by Application
6.4 Oncology Historic and Forecast Sales by Regions
6.5 Autoimmune & Immunological Disorders Historic and Forecast Sales by Regions
6.6 Hematological Disorders Historic and Forecast Sales by Regions
6.7 Infectious Diseases Historic and Forecast Sales by Regions
6.8 Others (Cardiovascular Disorders, etc.) Historic and Forecast Sales by Regions

7 . GLOBAL BIOLOGICS MARKET ANALYSIS BY MANUFACTURING

7.1 Overview by Manufacturing
7.2 Historical and Forecast Data
7.3 Analysis by Manufacturing
7.4 Outsourced Historic and Forecast Sales by Regions
7.5 In-house Historic and Forecast Sales by Regions

8 . GLOBAL BIOLOGICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE BIOLOGICS COMPANIES

9.1. Biologics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF BIOLOGICS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. AbbVie
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Amgen
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. AstraZeneca
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Bristol-Myers Squibb Company
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Eli Lilly
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Gilead Sciences Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. GlaxoSmithKline
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Johnson & Johnson Services Inc.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Merck & Co. Inc.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Novartis AG
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Pfizer Inc.
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments
10.14. F. Hoffmann-La Roche AG
- 10.14.1. Company Overview
- 10.14.2. Company Revenue
- 10.14.3. Products
- 10.14.4. Recent Developments